Clinical trials: Nerve Growth Factor
Depression - Major Depressive Disorder, Transcranial Magnetic Stimulation
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived…
- Conditions
- Depression - Major Depressive Disorder, Transcranial Magnetic Stimulation, Placebo
- Trial name
- NCT06667180
- Testing
- Low-intensity TMS
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Universidad de Guanajuato
Anesthesia, Neuroinflammation
Neuroinflammatory Biomarkers After General Anesthesia: A Comparison Study
This prospective, observational study investigates the impact of repeated general anesthesia exposure on neuroinflammatory biomarkers and neurotrophic factors.
- Conditions
- Anesthesia, Neuroinflammation, Cognitive Disorders
- Trial name
- NCT07388160
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Health Sciences Balikesir Hospital Eduation and Research
Phenylketonuria
Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With Phenylketonuria
Effect of L-carnitine supplementation on phenylalanine and brain-derived neurotrophic factor levels in infants and children with phenylketonuria L-carnitine is mainly obtained from foods such as red meat and milk that are limited…
- Trial name
- NCT06901323
- Testing
- L-carnitine
- Where
- Egypt
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM
The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane…
- Trial name
- NCT06397131
- Testing
- M-CHFM, CHFM
- Where
- 6 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Neurotech Pharmaceuticals
Stroke, Upper Extremity Paresis
Virtual Reality Training Dose for Arm Recovery After Stroke: Clinical and Blood Biomarker Responses
The goal of this clinical trial is to learn whether adding virtual reality (VR) training to conventional rehabilitation improves arm movement in adults who had a stroke 6 to 24 months earlier, and whether VR training 5 days a…
- Trial name
- NCT07919301
- Testing
- Neuroforma virtual reality training, Conventional rehabilitation program, Home exercise program
- Volunteers
- 72 people
- Sponsor
- Kutahya Health Sciences University
Chronic Pain
Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients
A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.
- Trial name
- BDNF (NCT05736575)
- Testing
- BDNF analysis (Elisa KIT)
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- Universidad Autonoma de Madrid
Neuroplasticity, Sensorimotor
Reversing Maladaptive Reorganization in Frail Brains
Neuroscientific models of maladaptive aging emphasize the loss of sensorimotor stimulation and reduced modulatory capacities as core processes in the development of maladaptive plastic changes of the brain and subsequent…
- Trial name
- FRAILBRAIN (NCT03666039)
- Testing
- Trainings app
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Non-inflammatory Neuropathic Pain, Healthy Subjects
Cortical Representation of Hyperalgesia Induced by Nerve Growth Factor
Intraepidermal injection of nerve growth factor results in a non-inflammatory hyperalgesia for thermal and mechanical stimuli. This hyperalgesia is similar to the pathological ailments of patients with neuropathic pain.
- Trial name
- LOGIN_NGF (NCT02159170)
- Testing
- NGF injection
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Prof Herta Flor
Breast Cancer, Brain Cancer
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors.
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers
- Trial name
- NCT02045368
- Testing
- IGF-Methotrexate conjugate
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- IGF Oncology, LLC
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Macular Telangiectasia Type 2 (MacTel)
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants…
- Trial name
- NCT06971939
- Testing
- NT-501/revakinagene taroretcel-lwey
- Where
- 26 sites in United States, Australia
- Volunteers
- 234 people
- Sponsor
- Neurotech Pharmaceuticals
Cognitive Dysfunction
Brain-Induced Neurotrophic Factor Levels in Patients Undergoing Coronary Artery Bypass Surgery
In patients undergoing coronary artery bypass surgery, the relationship between neurocognitive changes seen in the early period and brain-induced neurotrophic factor serum levels will be investigated.
- Trial name
- NCT04250935
- Testing
- Patients with cognitive dysfunction
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Bozok University
Cognitive Decline
Cognitive Function in Elderly Marathon Runners
There is substantial research on the effects of physical exercise on cognitive functions. However, less attention has been paid on the requirements of training intensity and length to enhance cognitive abilities in the elderly.
- Trial name
- APSOEM (NCT01045031)
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Depressive Disorder, Major Depression
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine
The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.
- Conditions
- Depressive Disorder, Major Depression, Depression, Depression, Unipolar
- Trial name
- VOR-IISR (NCT02969876)
- Testing
- Vortioxetine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Glioma
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet Derived Growth Factor Receptor (PDGFR)…
- Trial name
- NCT01140568
- Testing
- nilotinib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- David Piccioni, M.D., Ph.D
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 38 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Parkinson's Disease
GDNF Gene Therapy for Parkinson's Disease
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
- Trial name
- NCT04167540
- Testing
- AAV2-GDNF
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Amyotrophic Lateral Sclerosis
CNS10-NPC-GDNF for the Treatment of ALS
The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02943850
- Testing
- Stem cell (HPC) implantation, Stereotactic surgical device
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cedars-Sinai Medical Center